Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1899 participants
OBSERVATIONAL
2016-01-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort Study
NCT06123897
Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia
NCT06673966
Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders
NCT04218981
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
NCT02650102
Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia
NCT02964923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PMNP-Healthy Norms
Healthy Norms
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-Subclinical high-risk
Subclinical high-risk
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-Schizophrenia and Psychosis
Schizophrenia and Psychosis patient
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-MDD
major depressive disorder patient
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-ASD
autism spectrum disorder patient
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-BD
bipolar disorder patient
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Course of disease: \<24 months
* Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks
* No nuclear magnetic contraindications.
Exclusion Criteria
* Have a major physical disease or infectious disease
* History of coma and serious neurological disease 4.MRI contraindications.
13 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
mingjun Zhong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
mingjun Zhong
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Xiangya hospital of central south univerity
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NSFC82201664
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.